Association Between RUNX3 Promoter Methylation and Non-small Cell Lung Cancer: a Meta-analysis

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2014 Jul 1

PMID 24976992

Citations 6

Authors

Yali Liang

Lianping He

Hui Yuan

Yuelong Jin

Yingshui Yao

Affiliations

Soon will be listed here.

Abstract

Background: Runt-related transcription factor 3 (RUNX3) is a known regulator in the transforming growth factor (TGF)-β signaling pathway, which promoter methylation playing a crucial role in diverse neoplasias. However, the relationship between RUNX3 promoter methylation and non-small cell lung cancer (NSCLC) remains to be clarified.

Methods: We searched Pubmed, Embase, Cochrane Central, and Chinese Biological Medicine database, for articles published in English or Chinese until March 7, 2014. Our main analyses were focused on the association between RUNX3 promoter methylation and risk of NSCLC by meta-analysis methods. If heterogeneity was observed, we used random effects model to calculate the overall odds ratios, otherwise fixed effects model was used. Subgroup analyses and meta-regression analyses were employed to detect the sources of the heterogeneity. Sensitivity analysis was performed to evaluate the stability of our studies. A funnel plot and Egger's test were conducted to investigate any potential publication bias.

Results: A total of 1,368 samples from 13 literatures were involved in this meta-analysis. The pooled odds ratio (OR) of RUNX3 methylation in NSCLC specimens compared to non-cancer controls was 6.70 [95% confidence interval (CI): 4.64-9.67]. In the analysis of specimen-types subgroup, the summary OR was 5.79 (95% CI: 3.97-8.46) for tissue specimen subgroup, and that was 45.64 (95% CI: 5.89-353.72) for serum specimen subgroup. The ORs for the age ≤60 years, 60-65 years and >65 years subgroup were 5.19 (95% CI: 3.27-8.24), 9.45 (95% CI: 2.45-36.45) and 13.23 (95% CI: 5.59-31.28) respectively. The result of meta-regression indicated that age was fundamental source of heterogeneity (coefficient =0.61, P=0.046, adjusted R(2) =100%). No publication bias was detected. In cancer specimens, the RUNX3 methylation was associated with histological type of the NSCLC, but no significant differences were found for RUNX3 methylation in relation to gender, smoking history, tumor TNM stage or tumor differentiation level.

Conclusions: This meta-analysis of pooled data provides additional evidence to support a strong association between methylation of the RUNX3 promoter and NSCLC. RUNX3 methylation was increasing with age.

Citing Articles

Epigenetic Regulation of EMP/EMT-Dependent Fibrosis.

Sisto M, Lisi S Int J Mol Sci. 2024; 25(5).

PMID: 38474021 PMC: 10931844. DOI: 10.3390/ijms25052775.

Tumor DNA Methylation Profiles Enable Diagnosis, Prognosis Prediction, and Screening for Cervical Cancer.

Tu J, Chen S, Wu S, Wu T, Fan R, Kuang Z Int J Gen Med. 2022; 15:5809-5821.

PMID: 35789774 PMC: 9249661. DOI: 10.2147/IJGM.S352373.

Increased levels of long noncoding RNA LINC00691 correlate with poor prognosis in non-small-cell lung cancer patients.

Xie Y, Hu X J Clin Lab Anal. 2020; 34(8):e23357.

PMID: 32420681 PMC: 7439350. DOI: 10.1002/jcla.23357.

Aberrant methylation of can be a diagnostic biomarker for lung adenocarcinoma.

Pu W, Geng X, Chen S, Tan L, Tan Y, Wang A J Cancer. 2016; 7(15):2280-2289.

PMID: 27994665 PMC: 5166538. DOI: 10.7150/jca.15758.

Quantitative Histone Mass Spectrometry Identifies Elevated Histone H3 Lysine 27 (Lys27) Trimethylation in Melanoma.

Sengupta D, Byrum S, Avaritt N, Davis L, Shields B, Mahmoud F Mol Cell Proteomics. 2015; 15(3):765-75.

PMID: 26621846 PMC: 4813699. DOI: 10.1074/mcp.M115.053363.

References

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y . Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 2011; 303(1):21-8. DOI: 10.1016/j.canlet.2010.12.011. View

Damaschke N, Yang B, Bhusari S, Svaren J, Jarrard D . Epigenetic susceptibility factors for prostate cancer with aging. Prostate. 2013; 73(16):1721-30. PMC: 4237278. DOI: 10.1002/pros.22716. View

Kim T, Lee H, Hwang K, Lee M, Kim J, Bang Y . Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest. 2004; 84(4):479-84. DOI: 10.1038/labinvest.3700060. View

Yanada M, Yaoi T, Shimada J, Sakakura C, Nishimura M, Ito K . Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines. Oncol Rep. 2005; 14(4):817-22. View

Shames D, Girard L, Gao B, Sato M, Lewis C, Shivapurkar N . A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006; 3(12):e486. PMC: 1716188. DOI: 10.1371/journal.pmed.0030486. View

Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, Motoyama T . Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci. 2003; 94(7):589-92. PMC: 11160194. DOI: 10.1111/j.1349-7006.2003.tb01487.x. View

Omar M, Ito K, Nga M, Soo R, Peh B, Ismail T . RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status. Pathol Oncol Res. 2012; 18(4):783-92. DOI: 10.1007/s12253-011-9485-5. View

Suzuki M, Shigematsu H, Shames D, Sunaga N, Takahashi T, Shivapurkar N . DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer. 2005; 93(9):1029-37. PMC: 2361683. DOI: 10.1038/sj.bjc.6602837. View

10.

Li Q, Kim H, Kim W, Choi J, Lee Y, Kim H . Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun. 2004; 314(1):223-8. DOI: 10.1016/j.bbrc.2003.12.079. View

11.

Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S . Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med. 2010; 8:86. PMC: 2955578. DOI: 10.1186/1479-5876-8-86. View

12.

Subramaniam M, Chan J, Soong R, Ito K, Ito Y, Yeoh K . RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat. 2008; 113(1):113-21. DOI: 10.1007/s10549-008-9917-4. View

13.

Yoshino M, Suzuki M, Tian L, Moriya Y, Hoshino H, Okamoto T . Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers. Int J Oncol. 2009; 35(5):1201-9. DOI: 10.3892/ijo_00000437. View

14.

Risch A, Plass C . Lung cancer epigenetics and genetics. Int J Cancer. 2008; 123(1):1-7. DOI: 10.1002/ijc.23605. View

15.

Jeong P, Min B, Ha Y, Song P, Kim I, Ryu K . RUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: potential role in the prediction of tumor progression. Eur J Surg Oncol. 2012; 38(11):1095-100. DOI: 10.1016/j.ejso.2012.07.116. View

16.

Herzog C, Wang Y, You M . Allelic loss of distal chromosome 4 in mouse lung tumors localize a putative tumor suppressor gene to a region homologous with human chromosome 1p36. Oncogene. 1995; 11(9):1811-5. View

17.

Suzuki M, Wada H, Yoshino M, Tian L, Shigematsu H, Suzuki H . Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling. Ann Surg Oncol. 2009; 17(3):878-88. DOI: 10.1245/s10434-009-0739-3. View

18.

Tang Y, Wu F, Hu C . [RUNX3 promoter hypermethylation and prognosis of early surgically resected non-small cell lung cancers]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011; 36(7):650-4. DOI: 10.3969/j.issn.1672-7347.2011.07.012. View

19.

Labeau S, Van de Vyver K, Brusselaers N, Vogelaers D, Blot S . Prevention of ventilator-associated pneumonia with oral antiseptics: a systematic review and meta-analysis. Lancet Infect Dis. 2011; 11(11):845-54. DOI: 10.1016/S1473-3099(11)70127-X. View

20.

Bae S, Choi J . Tumor suppressor activity of RUNX3. Oncogene. 2004; 23(24):4336-40. DOI: 10.1038/sj.onc.1207286. View